Sarah S Donaldson

List of Publications by Year
in descending order

122 papers	8,463 citations	50276 46 h-index	46799 89 g-index
163 all docs	163 docs citations	163 times ranked	5104 citing authors

#	Article	IF	Citations
1	An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trials. Pediatric Blood and Cancer, 2022, 69, e29511.	1.5	37
2	Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatric Blood and Cancer, 2022, 69, e29644.	1.5	18
3	ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.. Journal of Clinical Oncology, 2022, 40, TPS11591-TPS11591.	1.6	1
4	Multimodality treatment including whole pleura radiation therapy for DICER1â€associated pediatric pleuropulmonary blastoma. Pediatric Blood and Cancer, 2021, 68, e29004.	1.5	0
5	Use of Audiovisual Assisted Therapeutic Ambience in Radiotherapy (AVATAR) for Anesthesia Avoidance in a Pediatric Patient With Down Syndrome. Advances in Radiation Oncology, 2021, 6, 100637.	1.2	1
6	Esophageal disease among childhood cancer survivorsâ€"A report from the Childhood Cancer Survivors Study. Pediatric Blood and Cancer, 2021, 68, e29043.	1.5	1
7	Rhabdomyosarcoma. Pediatric Blood and Cancer, 2021, 68, e28254.	1.5	18
8	Multidisciplinary management of newly diagnosed pediatric large cell neuroendocrine carcinoma of the lung causing hemoptysis. Pediatric Blood and Cancer, 2021, 68, e29182.	1.5	2
9	Excellent Outcome for Pediatric Patients With High-Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation. Journal of Clinical Oncology, 2021, 39, 2276-2283.	1.6	31
10	Local Control For High-Grade Nonrhabdomyosarcoma Soft Tissue Sarcoma Assigned to Radiation Therapy on ARST0332: A Report From the Childrens Oncology Group. International Journal of Radiation Oncology Biology Physics, 2021, 110, 821-830.	0.8	8
11	Use of cardiac radiation therapy as bridging therapy to CARâ€T for relapsed pediatric Bâ€cell acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2021, 68, e28870.	1.5	8
12	Outcomes for pediatric patients with osteosarcoma treated with palliative radiotherapy. Pediatric Blood and Cancer, 2020, 67, e27967.	1.5	21
13	Central Nervous System Relapse After Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia: A Single-Institution Experience. Journal of Adolescent and Young Adult Oncology, 2020, 9, 166-171.	1.3	6
14	Paraneoplastic Neurologic Symptoms in a Pediatric Patient with Hodgkin Lymphoma. Cancer Investigation, 2020, 39, 1-7.	1.3	1
15	Practice patterns and recommendations for pediatric imageâ€guided radiotherapy: A Children's Oncology Group report. Pediatric Blood and Cancer, 2020, 67, e28629.	1.5	11
16	Impact of Audiovisual-Assisted Therapeutic Ambience in Radiation Therapy (AVATAR) on Anesthesia Use, Payer Charges, and Treatment Time in Pediatric Patients. Practical Radiation Oncology, 2020, 10, e272-e279.	2.1	8
17	Virtual Radiation Oncology Clerkship During the COVID-19 Pandemic and Beyond. International Journal of Radiation Oncology Biology Physics, 2020, 108, 444-451.	0.8	20
18	Continuing Medical Student Education During the Coronavirus Disease 2019 (COVID-19) Pandemic: Development of a Virtual Radiation Oncology Clerkship. Advances in Radiation Oncology, 2020, 5, 732-736.	1.2	36

#	Article	IF	Citations
19	Successful Full-term Pregnancies After High-dose Pelvic Radiotherapy for Ewing Sarcoma: A Case Report. Journal of Pediatric Hematology/Oncology, 2020, 42, e807-e809.	0.6	0
20	Successful use of frameless stereotactic radiosurgery for treatment of recurrent brain metastases in an 18-month-old child. International Journal of Neuroscience, 2019, 129, 1234-1239.	1.6	1
21	Increased local failure for patients with intermediateâ€risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. Cancer, 2019, 125, 3242-3248.	4.1	55
22	Riskâ€based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. Cancer, 2019, 125, 2602-2609.	4.1	21
23	Treatment and outcomes in classic Hodgkin lymphoma postâ€transplant lymphoproliferative disorder in children. Pediatric Blood and Cancer, 2019, 66, e27803.	1.5	4
24	Treatment Approach and Outcomes in Infants With Localized Rhabdomyosarcoma: A Report From the Soft Tissue Sarcoma Committee of the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2019, 103, 19-27.	0.8	34
25	Larry Emanuel Kun, March 10, 1946-May 27, 2018. International Journal of Radiation Oncology Biology Physics, 2019, 103, 8-14.	0.8	0
26	Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma. Neuro-Oncology, 2018, 20, 1133-1141.	1.2	20
27	The Children's Oncology Group Radiation Oncology Discipline: 15ÂYears of Contributions to the Treatment of Childhood Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 860-874.	0.8	34
28	Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Childrenâ€™s Oncology Group. Journal of Clinical Oncology, 2018, 36, 2770-2777.	1.6	124
29	Temporal patterns in the risk of chronic health conditions in survivors of childhood cancer diagnosed 1970â€“99: a report from the Childhood Cancer Survivor Study cohort. Lancet Oncology, The, 2018, 19, 1590-1601.	10.7	179
30	Risk group accurately predicts outcome in primary extremity non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) in patients <30 years of age: Findings from Childrenâ€™s Oncology Group study ARST0332.. Journal of Clinical Oncology, 2018, 36, 10546-10546.	1.6	0
31	Orthotopic Liver Transplantation After Stereotactic Body Radiotherapy for Pediatric Hepatocellular Carcinoma with Central Biliary Obstruction and Nodal Involvement. Cureus, 2018, 10, e3499.	0.5	1
32	Longitudinal followâ€up of adult survivors of Ewing sarcoma: A report from the Childhood Cancer Survivor Study. Cancer, 2017, 123, 2551-2560.	4.1	47
33	Chemoradiation impairs normal developmental cortical thinning in medulloblastoma. Journal of Neuro-Oncology, 2017, 133, 429-434.	2.9	5
34	45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy. Pediatric Blood and Cancer, 2017, 64, e26540.	1.5	33
35	Initial clinical outcomes of audiovisual-assisted therapeutic ambience in radiation therapy (AVATAR). Practical Radiation Oncology, 2017, 7, 311-318.	2.1	19
36	Stereotactic body radiotherapy for pediatric hepatocellular carcinoma with central biliary obstruction. Pediatric Blood and Cancer, 2017, 64, e26330.	1.5	6

#	Article	IF	Citations
37	Reply to Second malignancies in Ewing sarcoma survivors. Cancer, 2017, 123, 4075-4076.	4.1	0
38	Ethics in Radiation Oncology and the American Society for Radiation Oncology's Role. International Journal of Radiation Oncology Biology Physics, 2017, 99, 247-249.	0.8	2
39	Reported missing founding member of the International Society of Paediatric Oncology â€¦found. Pediatric Blood and Cancer, 2017, 64, e26523.	1.5	1
40	The Parotid Gland is an Underrecognized Organ at Risk for Craniospinal Irradiation. Technology in Cancer Research and Treatment, 2016, 15, 472-479.	1.9	8
41	Radiation-Related New Primary Solid Cancers in the Childhood Cancer Survivor Study: Comparative Radiation Dose Response and Modification of Treatment Effects. International Journal of Radiation Oncology Biology Physics, 2016, 94, 800-807.	0.8	107
42	Partial orbit irradiation achieves excellent outcomes for primary orbital lymphoma. Practical Radiation Oncology, 2016, 6, 255-261.	2.1	11
43	Improved Outcomes after Autologous Bone Marrow Transplantation for Children with Relapsed or Refractory Hodgkin Lymphoma: Twenty Years Experience at a Single Institution. Biology of Blood and Marrow Transplantation, 2015, 21, 326-334.	2.0	19
44	Delayed primary excision with subsequent modification of radiotherapy dose for intermediateâ€risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee. International Journal of Cancer, 2015, 137, 204-211.	5.1	50
45	Homage to M. Vera Peters, MD. International Journal of Radiation Oncology Biology Physics, 2015, 92, 5-7.	0.8	1
46	Management of Nodular Lymphocyte Predominant Hodgkin Lymphoma in the Modern Era. International Journal of Radiation Oncology Biology Physics, 2015, 92, 67-75.	0.8	9
47	Extraskeletal Osteosarcoma of the Hand: The Role of Marginal Excision and Adjuvant Radiation Therapy. Hand, 2015, 10, 602-606.	1.2	6
48	Local Control for Intermediate-Risk Rhabdomyosarcoma: Results From D9803 According to Histology, Group, Site, and Size: AÂReport From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 93, 1071-1076.	0.8	55
49	Recent advances in understanding and managing rhabdomyosarcoma. F1000prime Reports, 2015, 7, 59.	5.9	19
50	Successful Treatment with Temozolomide Combined with Chemoradiotherapy and Surgery of a Metastatic Undifferentiated Soft Tissue Sarcoma with Relapse in the Central Nervous System of a Young Adult. Journal of Adolescent and Young Adult Oncology, 2014, 3, 100-103.	1.3	0
51	Quality of life outcomes in proton and photon treated pediatric brain tumor survivors. Radiotherapy and Oncology, 2014, 113, 89-94.	0.6	93
52	Tribute to Professor Maurice Tubiana. International Journal of Radiation Oncology Biology Physics, 2014, 88, 755-756.	0.8	1
53	Survival and Neurocognitive Outcomes After Cranial or Craniospinal Irradiation Plus Total-Body Irradiation Before Stem Cell Transplantation in Pediatric Leukemia Patients With Central Nervous System Involvement. International Journal of Radiation Oncology Biology Physics, 2014, 89, 67-74.	0.8	29
54	Secondary breast angiosarcoma and germ line BRCA mutations: discussion of genetic susceptibility. Journal of Radiation Oncology, 2013, 2, 331-335.	0.7	4

#	Article	IF	Citations
55	Low-Dose Radiation Therapy (2 Gy Ã— 2) in the Treatment of Orbital Lymphoma. International Journal of Radiation Oncology Biology Physics, 2013, 86, 930-935.	0.8	96
56	The Effect of Radiation Timing on Patients With High-Risk Features of Parameningeal Rhabdomyosarcoma: An Analysis of IRS-IV and D9803. International Journal of Radiation Oncology Biology Physics, 2013, 87, 512-516.	0.8	35
57	Relapse after treatment of pediatric hodgkin lymphoma: Outcome and role of surveillance after end of therapy. Pediatric Blood and Cancer, 2013, 60, 1458-1463.	1.5	25
58	Association Between Radiotherapy vs No Radiotherapy Based on Early Response to VAMP Chemotherapy and Survival Among Children With Favorable-Risk Hodgkin Lymphoma. JAMA - Journal of the American Medical Association, 2012, 307, 2609-16.	7.4	91
59	Effect of Radiotherapy Techniques (IMRT vs. 3D-CRT) on Outcome in Patients With Intermediate-Risk Rhabdomyosarcoma Enrolled in COG D9803â€"A Report From the Childrenâ€™s Oncology Group. International Journal of Radiation Oncology Biology Physics, 2012, 82, 1764-1770.	0.8	61
60	Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group. Pediatric Blood and Cancer, 2011, 57, 76-83.	1.5	74
61	Influence of Noncompliance With Radiation Therapy Protocol Guidelines and Operative Bed Recurrences for Children With Rhabdomyosarcoma and Microscopic Residual Disease: A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2011, 80, 333-338.	0.8	42
62	Regional Nodal Involvement and Patterns of Spread Along In-Transit Pathways in Children With Rhabdomyosarcoma of the Extremity: A Report From the Children's Oncology Group. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1151-1157.	0.8	39
63	Prognostic Significance and Tumor Biology of Regional Lymph Node Disease in Patients With Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2011, 29, 1304-1311.	1.6	102
64	Early Treatment Failure in Intermediate-Risk Rhabdomyosarcoma: Results From IRS-IV and D9803â€"A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2010, 28, 4228-4232.	1.6	26
65	Vincristine, Actinomycin, and Cyclophosphamide Compared With Vincristine, Actinomycin, and Cyclophosphamide Alternating With Vincristine, Topotecan, and Cyclophosphamide for Intermediate-Risk Rhabdomyosarcoma: Children's Oncology Group Study D9803. Journal of Clinical Oncology, 2009, 27, 5182-5188.	1.6	320
66	Treatment of Pediatric Hodgkin Lymphoma. Current Treatment Options in Oncology, 2008, 9, 81-94.	3.0	23
67	Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group. Journal of Clinical Oncology, 2007, 25, 362-369.	1.6	190
68	Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's Disease. Journal of Clinical Oncology, 2007, 25, 332-337.	1.6	125
69	Advances Toward an Understanding of Brainstem Gliomas. Journal of Clinical Oncology, 2006, 24, 1266-1272.	1.6	219
70	Cyclophosphamide Dose Intensification during Induction Therapy for Intermediate-Risk Pediatric Rhabdomyosarcoma Is Feasible but Does Not Improve Outcome. Clinical Cancer Research, 2004, 10, 6072-6079.	7.0	60
71	Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease. Journal of Clinical Oncology, 2004, 22, 4541-4550.	1.6	73
72	Ewing sarcoma: Radiation dose and target volume. Pediatric Blood and Cancer, 2004, 42, 471-476.	1.5	87

#	Article	IF	Citations
73	High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation for Recurrent or Refractory Pediatric Hodgkin's Disease: Results and Prognostic Indices. Journal of Clinical Oncology, 2004, 22, 4532-4540.	1.6	85
74	Subspecialty training and certification for radiation oncology. Journal of the American College of Radiology, 2004, 1, 488-492.	1.8	8
75	A discourse: The 2002 Wataru W. Sutow lecture Hodgkin disease in children?perspectives and progress. Medical and Pediatric Oncology, 2003, 40, 73-81.	1.0	11
76	Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcomaâ€"A Report From the Intergroup Rhabdomyosarcoma Study IV. Journal of Clinical Oncology, 2003, 21, 78-84.	1.6	419
77	VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkinâ€™s Disease: Results of a Prospective Clinical Trial. Journal of Clinical Oncology, 2002, 20, 3081-3087.	1.6	116
78	Treatment of Unfavorable Childhood Hodgkinâ€™s Disease With VEPA and Low-Dose, Involved-Field Radiation. Journal of Clinical Oncology, 2002, 20, 3088-3094.	1.6	73
79	Primary radiotherapy for localized orbital MALT lymphoma. International Journal of Radiation Oncology Biology Physics, 2002, 52, 657-663.	0.8	119
80	Pediatric Hodgkinâ€™s diseaseâ€"up, up, and beyond. International Journal of Radiation Oncology Biology Physics, 2002, 54, 1-8.	0.8	17
81	Intergroup Rhabdomyosarcoma Study-IV: Results for Patients With Nonmetastatic Disease. Journal of Clinical Oncology, 2001, 19, 3091-3102.	1.6	962
82	What constitutes optimal therapy for patients with rhabdomyosarcoma of the female genital tract?. Cancer, 2001, 91, 2454-2468.	4.1	135
83	Rhabdomyosarcoma of the parotid region occurring in childhood and adolescence. Cancer, 2001, 92, 3135-3146.	4.1	30
84	Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcomaâ€"a report from the IRSG 1 1For a complete list of the members of the Childrenâ€™s Oncology Group Soft Tissue Sarcoma Committee (formerly Intergroup Rhabdomyosarcoma Group) representing the Childrenâ€™s Oncology Group and the Quality Assurance Review Center, see the Appendix.. International Journal of Radiation Oncology Biology Physics, 2001, 51, 718-728.	0.8	200
85	The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major Lessons From the IRS-I Through IRS-IV Studies as Background for the Current IRS-V Treatment Protocols. Sarcoma, 2001, 5, 9-15.	1.3	246
86	Controversies in the Management of Paratesticular Rhabdomyosarcoma: Is Staging Retroperitoneal Lymph Node Dissection Necessary for Adolescents With Resected Paratesticular Rhabdomyosarcoma?. Seminars in Pediatric Surgery, 2001, 10, 146-152.	1.1	121
87	Management of children with metastatic spinal myxopapillary ependymoma using craniospinal irradiation. Medical and Pediatric Oncology, 2000, 35, 443-445.	1.0	29
88	New methods for precision radiation therapy exceed biological and clinical knowledge and institutional resources needed for implementation. Medical Physics, 2000, 27, 2477-2479.	3.0	3
89	Indications for Radiotherapy and Chemotherapy After Complete Resection in Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Studies I to III. Journal of Clinical Oncology, 1999, 17, 3468-3475.	1.6	152
90	Late complications of therapy in 213 children with localized, nonorbital soft-tissue sarcoma of the head and neck: A descriptive report from the Intergroup Rhabdomyosarcoma Studies (IRS)-II and - III. , 1999, 33, 362-371.		167

#	Article	IF	Citations
91	Primary and metastatic rhabdomyosarcoma in the breast: Neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study. , 1997, 29, 181-189.		94
92	Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. , 1997, 79, 2435-2439.		56
93	Primary and metastatic rhabdomyosarcoma in the breast: neoplasms of adolescent females, a report from the Intergroup Rhabdomyosarcoma Study. Medical and Pediatric Oncology, 1997, 29, 181-189.	1.0	3
94	A Feasibility, Toxicity, and Early Response Study of Etoposide, Ifosfamide, and Vincristine for the Treatment of Children with Rhabdomyosarcoma: A Report from the Intergroup Rhabdomyosarcoma Study (IRS) IV Pilot Study. The American Journal of Pediatric Hematology/oncology, 1997, 19, 124-129.	1.3	46
95	Cost effectiveness and outcome assessment of magnetic resonance imaging in diagnosing cord compression. Cancer, 1995, 75, 2579-2586.	4.1	22
96	Radiation induced height impairment in pediatric Hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1994, 28, 85-92.	0.8	82
97	The intergroup rhabdomyosarcoma study-II. Cancer, 1993, 71, 1904-1922.	4.1	547
98	Prognostic features of ewing sarcoma on plain radiograph and computed tomography scan after initial treatment. A pediatric oncology group study (8346). Cancer, 1993, 72, 2503-2510.	4.1	20
99	Langerhans' cell histiocytosis presenting with the superior vena cava syndrome: A case report. Medical and Pediatric Oncology, 1993, 21, 456-459.	1.0	14
100	Radiotherapy is successful treatment for orbital lymphoma. International Journal of Radiation Oncology Biology Physics, 1993, 26, 59-66.	0.8	98
101	Treatment of Orbital Lymphoid Tumors with Electron Beams. Frontiers of Radiation Therapy and Oncology, 1991, 25, 187-200.	1.4	11
102	Making choices in the staging of children with Hodgkin's disease. Medical and Pediatric Oncology, 1991, 19, 211-213.	1.0	9
103	Reviews: Special Nutritional Needs of Children with Malignancies: A Review. Journal of Parenteral and Enteral Nutrition, 1990, 14, 315-324.	2.6	115
104	Topography of Childhood Tumors: Pediatric Coding System. Pediatric Hematology and Oncology, 1986, 3, 249-258.	0.8	24
105	Neuro-ocular damage in pediatric oncology patients: Predictor of long-term visual disability or tool for limiting toxicity?. Medical and Pediatric Oncology, 1986, 14, 262-270.	1.0	7
106	Radiotherapy of lymphoid diseases of the orbit. International Journal of Radiation Oncology Biology Physics, 1985, 11, 371-379.	0.8	71
107	The value of adjuvant chemotherapy in the management of sarcomas in children. Cancer, 1985, 55, 2184-2197.	4.1	55
108	Nutritional Support as an Adjunct to Radiation Therapy. Journal of Parenteral and Enteral Nutrition, 1984, 8, 302-310.	2.6	57

#	Article	IF	Citations
109	Thyroid dysfunction after radiotherapy in children with Hodgkin's disease. Cancer, 1984, 53, 878-883.	4.1	226
110	Acute nonlymphocytic leukemia developing during the course of Ewing's sarcoma. Medical and Pediatric Oncology, 1984, 12, 194-200.	1.0	16
111	Editorial: Is involved field irradiation alone optimal therapy for a child with Hodgkin's disease?. Medical and Pediatric Oncology, 1984, 12, 322-324.	1.0	7
112	Safety of Intravenous Hyperalimentation in Children with Malignancies: A Cooperative Group Trial. Journal of Parenteral and Enteral Nutrition, 1982, 6, 291-294.	2.6	15
113	A prospective randomized clinical trial of total parenteral nutrition in children with cancer. Medical and Pediatric Oncology, 1982, 10, 129-139.	1.0	60
114	Electrophysiologic evidence of subclinical injury to the posterior columns of the human spinal cord after therapeutic radiation. Cancer, 1982, 50, 2815-2819.	4.1	26
115	The nutritional effects of cancer and its therapy. Nutrition and Cancer, 1980, 2, 22-29.	2.0	12
116	Alterations of nutritional status.Impact of chemotherapy and radiation therapy. Cancer, 1979, 43, 2036-2052.	4.1	154
117	Herpes zoster and varicella infections in children with hodgkin's disease.An analysis of contributing factors. Cancer, 1978, 41, 95-99.	4.1	83
118	Epithelioid granulomas associated with Hodgkin's disease.Clinical correlations in 55 previously untreated patients. Cancer, 1978, 41, 562-567.	4.1	210
119	Bacterial infections in pediatric Hodgkin's disease.Relationship to radiotherapy, chemotherapy and splenectomy. Cancer, 1978, 41, 1949-1958.	4.1	91
120	Pregnancy following oophoropexy and total nodal irradiation in women with Hodgkinapos;s disease. Cancer, 1976, 38, 2263-2268.	4.1	124
121	Non-Hodgkin's lymphomas. VI. Results of treatment in childhood. Cancer, 1974, 34, 204-211.	4.1	66
122	Rhabdomyosarcoma of head and neck in children. Cancer, 1973, 31, 26-35.	4.1	235